Triple therapy has comparable results in relapsed/refractory B-cell lymphoma
Atezolizumab, obinutuzumab and venetoclax combined produced a durable response in relapsed/refractory diffuse large B-cell lymphoma but presented best in low tumor burden cases, according to a poster presented at ASCO20 Virtual Scientific Sessions.
“The atezolizumab, obinutuzumab and venetoclax combination appears to be well tolerated,” Charles Herbaux, MD, MSc, of the Centre Hospitalier Régional Universitaire de Lille, Institute of Hematolog-Tranfusion, Lille, France, said in the recorded presentation. “The overall metabolic response rate at the end of induction is comparable with currently available treatment options in this heavily pretreated population.”
The cohort presented included biopsy-confirmed relapsed/refractory DLBCL that relapsed after at least one line of therapy. Each therapy was dosed in its regimen and primary endpoint was overall metabolic response rate after eight cycles.
In this analysis, 58 patients had a median follow-up of 9 months.
“The overall metabolic response rate at the end of induction was measured at 23%, including 18% of complete remission,” Herbaux said. “To date, these responses seem durable with only three reported relapses.”
He added that overall metabolic response rate was better in patients with “highest diameter mass below 5 cm” (38.5% in < 5 cm vs. 10.3% in > 5 cm; P = .02).
Seventy-eight percent of patients stopped all three treatments, mostly due to disease progress, Herbeaux said. Grade 3 to 4 adverse events occurred in 48 patients.
“Despite major advances introduced by immunochemotherapy, relapsed and refractory diffuse large B-cell lymphoma treatment remains challenging,” he said. “Combining two more targeted therapies with agents that enhance antitumor immunity represents an attractive treatment paradigm.”
He added that this ongoing study includes two other cohorts – follicular lymphoma and indolent non-Hodgkin lymphoma.
Collapse
Herbaux C, et al. Abstract 8053. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.
Read more about